Taken together, our findings strongly suggest the pathogenic importance of the CXCL13/CXCR5 axis and PD-1+CXCL13+ T cells as a treatment target in LR-CHL. The gene discussed is CXCL13; the disease is classic Hodgkin lymphoma.